Procter & Gamble (NYSE: PG) just kicked off its fiscal 2017 with a bang. Organic sales rose in each of its five product divisions thanks to a good mix of higher volume and increasing prices.
The healthcare segment stood out from the rest, though, with revenue growth that was far above the company’s overall 3% result:
Segment